SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lasa Supergenerics - Quaterly Results

13 Aug 2025 Evaluate
The sales moved down -35.10% to Rs. 200.12 millions for the June 2025 quarter as compared to Rs. 308.36 millions during the corresponding quarter last year.The Net Loss for the quarter ended June 2025 is Rs. -211.20 millions as compared to Net Loss of Rs. -27.32 millions of corresponding quarter ended June 2024Operating profit Margin for the quarter ended June 2025 slipped to -3.68% as compared to 18.02% of corresponding quarter ended June 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202506 202406 % Var 202506 202406 % Var 202503 202403 % Var
Sales 200.12 308.36 -35.10 200.12 308.36 -35.10 1424.48 1043.35 36.53
Other Income 1.34 0.05 2580.00 1.34 0.05 2580.00 50.12 1.02 4813.73
PBIDT -3.68 18.02 -120.42 -3.68 18.02 -120.42 112.77 22.64 398.10
Interest 0.26 8.72 -97.02 0.26 8.72 -97.02 26.92 19.32 39.34
PBDT -209.69 9.30 -2354.73 -209.69 9.30 -2354.73 -70.84 -84.41 -16.08
Depreciation 15.70 27.94 -43.81 15.70 27.94 -43.81 123.00 106.73 15.24
PBT -225.39 -18.64 1109.17 -225.39 -18.64 1109.17 -193.84 -191.14 1.41
TAX -14.19 8.68 -263.48 -14.19 8.68 -263.48 -46.26 26.18 -276.70
Deferred Tax -14.19 8.68 -263.48 -14.19 8.68 -263.48 -46.26 26.18 -276.70
PAT -211.20 -27.32 673.06 -211.20 -27.32 673.06 -147.58 -217.32 -32.09
Equity 501.01 501.01 0.00 501.01 501.01 0.00 501.01 501.01 0.00
PBIDTM(%) -1.84 5.84 -131.47 -1.84 5.84 -131.47 7.92 2.17 264.84

Lasa Supergenerics Share Price

8.14 0.25 (3.17%)
16-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1693.15
Dr. Reddys Lab 1221.25
Cipla 1230.75
Zydus Lifesciences 939.20
Lupin 2326.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×